lifestyle.newsblaze.com

Author: ELI LILLY AND COMPANY

Lilly’s Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer

February 16, 2026
Lilly to acquire Orna Therapeutics to advance cell therapies

February 12, 2026
Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

February 4, 2026
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility

January 30, 2026
Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement

January 21, 2026
Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer

January 20, 2026
Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight

January 14, 2026
Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight

January 13, 2026
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases

January 7, 2026
Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial

December 30, 2025